These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30058895)

  • 1. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease.
    Sprague SM; Strugnell SA; Bishop CW
    Expert Rev Endocrinol Metab; 2017 Sep; 12(5):289-301. PubMed ID: 30058895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Cozzolino M; Ketteler M
    Expert Opin Pharmacother; 2019 Dec; 20(17):2081-2093. PubMed ID: 31675257
    [No Abstract]   [Full Text] [Related]  

  • 3. Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation.
    Petkovich M; Melnick J; White J; Tabash S; Strugnell S; Bishop CW
    J Steroid Biochem Mol Biol; 2015 Apr; 148():283-9. PubMed ID: 25446887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients.
    Germain MJ; Paul SK; Fadda G; Broumand V; Nguyen A; McGarvey NH; Gitlin MD; Bishop CW; Csomor P; Strugnell S; Ashfaq A
    BMC Nephrol; 2022 Nov; 23(1):362. PubMed ID: 36368937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease.
    Sprague SM; Crawford PW; Melnick JZ; Strugnell SA; Ali S; Mangoo-Karim R; Lee S; Petkovich PM; Bishop CW
    Am J Nephrol; 2016; 44(4):316-325. PubMed ID: 27676085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
    Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol.
    Fadda G; Germain MJ; Broumand V; Nguyen A; McGarvey N; Gitlin M; Bishop CW; Ashfaq A
    Am J Nephrol; 2021; 52(10-11):798-807. PubMed ID: 34818216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease.
    Strugnell SA; Csomor P; Ashfaq A; Bishop CW
    Kidney Dis (Basel); 2023 May; 9(3):206-217. PubMed ID: 37497207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-Release Calcifediol: A Data Journey from Phase 3 Studies to Real-World Evidence Highlights the Importance of Early Treatment of Secondary Hyperparathyroidism.
    Merante D; Schou H; Morin I; Manu M; Ashfaq A; Bishop C; Strugnell S
    Nephron; 2024 Apr; ():1-10. PubMed ID: 38657576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease.
    Sprague SM; Silva AL; Al-Saghir F; Damle R; Tabash SP; Petkovich M; Messner EJ; White JA; Melnick JZ; Bishop CW
    Am J Nephrol; 2014; 40(6):535-45. PubMed ID: 25572630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD.
    Kalantar-Zadeh K; Hollenbeak CS; Arguello R; Snyder S; Ashfaq A
    J Med Econ; 2020 Mar; 23(3):308-315. PubMed ID: 31726882
    [No Abstract]   [Full Text] [Related]  

  • 13. [Extended release calcifediol and paricalcitol in the treatment of secondary hyperparathyroidism: a network meta-analysis of indirect comparison].
    Franchi M; Galassi A; Corrao G
    G Ital Nefrol; 2023 Feb; 40(1):. PubMed ID: 36883925
    [No Abstract]   [Full Text] [Related]  

  • 14. Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism.
    Bishop CW; Strugnell SA; Csomor P; Kaiser E; Ashfaq A
    Am J Nephrol; 2022; 53(6):446-454. PubMed ID: 35551374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis.
    Franchi M; Gunnarsson J; Gonzales-Parra E; Ferreira A; Ström O; Corrao G
    J Clin Endocrinol Metab; 2023 Oct; 108(11):e1424-e1432. PubMed ID: 37235771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease.
    Galassi A; Bellasi A; Ciceri P; Pivari F; Conte F; Cozzolino M
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1073-1084. PubMed ID: 28846459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency.
    Galassi A; Ciceri P; Porata G; Iatrino R; Boni Brivio G; Fasulo E; Magagnoli L; Stucchi A; Frittoli M; Cara A; Cozzolino M
    Expert Opin Drug Saf; 2021 Nov; 20(11):1333-1349. PubMed ID: 33993809
    [No Abstract]   [Full Text] [Related]  

  • 19. Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future.
    Brandenburg V; Ketteler M
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of calcifediol supplementation on markers of chronic kidney disease-mineral and bone disorder in dogs with chronic kidney disease.
    Parker VJ; Rudinsky AJ; Benedict JA; Beizaei A; Chew DJ
    J Vet Intern Med; 2020 Nov; 34(6):2497-2506. PubMed ID: 33128421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.